Ciccarelli A, Daly AF, Beckers A. The epidemiology of prolactinomas. Pituitary 2005, 8: 3-6.
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006, 91: 4769-75. (Pubitemid 44917305)
Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27: 485-534.
Colao A, Di Sarno A, Samacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997, 82: 876-83. (Pubitemid 27106605)
Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009, 23: 575-96.
Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996, 14: 228-38. (Pubitemid 26128812)
Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002, 11: 787-800. (Pubitemid 34618811)
Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999, 84: 2518-22.
Webster J, Piscitelli G, Polli A, Ferrari Cl, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994, 331: 904-9. (Pubitemid 24299871)
Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med 1995, 24: 753-7.
Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000, 85: 2247-52. (Pubitemid 32269250)
Vance ML, Upper M, Klibanski A, Biller BM, Samaan NA, Molitch ME. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med 1990, 112: 668-73. (Pubitemid 20137175)
Barlier A, Jaquet P. Quinagolide~a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 2006, 154: 187-95.
Di Sarno A, Landi ML, Cappabianca Pet al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001, 86: 5256-61. (Pubitemid 33070245)
Ono M, Miki N, Kawamata T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008, 93: 4721-7.
Behan LA, Draman MS, Moran C, et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary 2009, Feb 4 [Epub ahead of print].
Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH. Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 1997, 82: 2962-5.
Lania AG, Ferrero S, Pivonello R, et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor co-incident with GNAS gene mutation. J Clin Endocrinol Metab 2010, 95: 13-7.
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000, 80: 1523-631.
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998, 78: 189-225.
Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001, 22: 724-63. (Pubitemid 34214293)
Pivonello R, Ferone D, Lombardi G, Colao A, Lamberts SW, Hofland U. Novel insights in dopamine receptor physiology. Eur J Endocrinol 2007, 156 (Suppl 1): S13-21.
Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. Nature 1989, 342: 926-9. (Pubitemid 20021339)
Senogles SE. D2s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol 2003, 209: 61-9. (Pubitemid 37353083)
Lew AM, Elsholtz HP. A dopamine-responsive domain in the N-terminal sequence of Pit-1. Transcriptional inhibition in endocrine cell types. J Biol Chem 1995, 270: 7156-60.
Friedman E, Adams EF, Hoog A, et al. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors. J Clin Endocrinol Metab 1994, 78: 568-74. (Pubitemid 24083293)
Pellegrini I, Rasolonjanahary R, Gunz G, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989, 69: 500-9.
Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994, 60: 314-22.
Montmayeur JP, Guiramand J, Borrelli E. Preferential coupling between dopamine D2 receptors and G-proteins. Mol Endocrinol 1993, 7: 161-70. (Pubitemid 23066858)
Filopanti M, Barbieri AM, Angioni AR, et al. Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 2008, 8: 357-63.
Missale C, Losa M, Sigala S, Balsari A, Giovanelli M, Spano PF. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol 1996, 10: 272-85. (Pubitemid 26082699)
Missale C, Boroni F, Losa M, et al. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci U S A 1993, 90: 7961-5. (Pubitemid 23260834)
Passos VQ, Fortes MA, Giannella-Neto D, Bronstein MD. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 2009, 89: 163-70.
Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002, 87: 457-65. (Pubitemid 34158204)
Daly AF, Tichomirowa MA, Petrossians P, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010, 95: E373-83.
Vroonen L, Tamagno G, Naves L, et al. Characterization of prolactinomas resistant to dopaminergic agonists. ENDO 2010; San Diego, CA: Endocrine ReviewsJune 2010, 31 (Suppl 1): S2508 (abstract).
Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996, 135: 413-20. (Pubitemid 26364941)
Rohmer V, Freneau E, Morange I, Simonetta C. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse. Ann Endocrinol (Paris) 2000, 61: 411-7.
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007, 356: 29-38. (Pubitemid 46041751)
Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008, 159: 1-5. (Pubitemid 351969123)
Valassi E, Klibanski A, Biller BM. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010, 95: 1025-33.
Hamilton DK, Vance ML, Boulos PT, Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005, 8: 53-60. (Pubitemid 44680086)
Neff LM, Weil M, Cole A, et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 2007, 10: 81-6. (Pubitemid 46562811)
Byrne S, Karapetis C, Vrodos N. A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 2009, 16: 1694-6.
Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 2007, 38: 185-9. (Pubitemid 44880216)
Sheehan J, Rainey J, Nguyen J, Grimsdale R, Han S. Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg 2011, 114: 354-8.
Fusco A, Gunz G, Jaquet P, et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 2008, 158: 595-603. (Pubitemid 351639596)
Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005, 26: 400-22. (Pubitemid 40686651)
